Biogen - BIIB Stock Forecast, Price & News

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Analyst Ratings Changes

Several research firms have weighed in on BIIB. Wells Fargo & Company raised Biogen from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $235.00 to $265.00 in a research report on Monday, April 18th. Truist Financial dropped their target price on Biogen from $320.00 to $270.00 and set a "buy" rating for the company in a research report on Thursday, July 21st. Barclays dropped their target price on Biogen from $210.00 to $200.00 and set an "equal weight" rating for the company in a research report on Thursday, July 21st. Cowen dropped their target price on Biogen from $285.00 to $270.00 and set an "outperform" rating for the company in a research report on Thursday, July 21st. Finally, UBS Group lowered their price objective on Biogen to $238.00 in a research report on Friday, July 22nd. Thirteen analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Biogen has a consensus rating of "Moderate Buy" and an average target price of $257.36.

Biogen Price Performance

Shares of NASDAQ:BIIB traded down $0.10 on Monday, hitting $218.10. The company had a trading volume of 28,868 shares, compared to its average volume of 1,202,480. The company has a current ratio of 1.94, a quick ratio of 1.68 and a debt-to-equity ratio of 0.53. Biogen has a 52-week low of $187.16 and a 52-week high of $351.86. The business has a 50 day moving average of $208.10 and a 200 day moving average of $209.06. The company has a market cap of $31.65 billion, a PE ratio of 15.56, a PEG ratio of 1.00 and a beta of 0.40.

Biogen (NASDAQ:BIIB - Get Rating) last issued its quarterly earnings data on Wednesday, July 20th. The biotechnology company reported $5.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.09 by $1.16. Biogen had a return on equity of 22.36% and a net margin of 19.36%. The business had revenue of $2.59 billion for the quarter, compared to the consensus estimate of $2.48 billion. During the same period in the prior year, the business earned $5.68 earnings per share. The business's revenue was down 6.7% on a year-over-year basis. As a group, equities analysts anticipate that Biogen will post 16.36 earnings per share for the current fiscal year.